All Oncology News

The resubmission of the BLA for RP1 has been accepted for review by the FDA for its use in combination with nivolumab in advanced melanoma.

R. Lor Randall, MD, FACS, reviews a longitudinal study in osteosarcoma showing a strong correlation between ctDNA status and clinical outcomes such as EFS.

In an MAIC, mogamulizumab led to an OS improvement vs vorinostat in patients with relapsed/refractory mycosis fungoides or Sézary syndrome.

Topical tofacitinib is tolerable and has shown preliminary efficacy in patients with early-stage mycosis fungoides.

Distinct somatic mutation profiles separated responders from non-responders to mogamulizumab in mycosis fungoides and Sézary syndrome.

Vernon Sondak, MD, discusses CSCC risk classification, adjuvant cemiplimab in extremely high-risk disease, and the promise of neoadjuvant immunotherapy.

Shane Lloyd, MD, MHS, and Christos Vaklavas, MD, were selected as new Huntsman Cancer Institute Translational Scholars for their leadership in bridging laboratory discoveries with clinical innovation.

Hagop Kantarjian, MD, discusses the arsenal of TKIs approved for chronic myeloid leukemia and how to navigate them regarding treatment selection.

Daratumumab-based retreatment remained active in a broadly inclusive, transplant-ineligible newly diagnosed multiple myeloma population.

Experts convened during an OncLive Scientific Interchange and Workshop to discuss evolving biomarker utilization and sequencing strategies in uveal melanoma.

The FDA has approved sacituzumab govitecan monotherapy and in combination with pembrolizumab in frontline TNBC.

Izalontamab brengitecan has been approved in China for recurrent/metastatic NPC following disease progression on chemotherapy and PD-1/PD-L1 inhibition.

The FDA has approved palbociclib plus trastuzumab, with/without pertuzumab, and ET as maintenance in HR+, HER2+ metastatic breast cancer.

The European Commission approved perioperative pembrolizumab plus enfortumab vedotin for patients with cisplatin-ineligible resectable MIBC.

Mayo Clinic scientists have revealed the molecular structures of PKCβ, a key protein linked to cancer and neurological diseases.

Priya Rastogi, MD, discusses findings from a sub-study of the GeparDouze trial evaluating the effects of ctDNA positivity on treatment outcomes in TNBC.

An off-the-shelf BCMA-directed CAR T-cell therapy generated a 100% overall response rate and universal MRD negativity in heavily pretreated myeloma.

Christian Grommes, MD, and Ashley Sumrall, MD, FACP, FASCO, discuss the phase 3 IGNITE trial of tirabrutinib in PCNSL.

The NCCN has included tumor-informed multiplex PCR ctDNA-MRD testing in the treatment approach for patients with MIBC.

The European Commission approved first-line sacituzumab govitecan as monotherapy for unresectable/metastatic TNBC not eligible for PD-(L)1 inhibition.

JCI Insight study identified IL1RAP as a driver of treatment resistance, with V Foundation funding advancing the work toward a clinical trial at Sylvester.

OS was not improved with sigvotatug vedotin vs docetaxel in patients with pretreated, locally advanced, unresectable, or metastatic nonsquamous NSCLC.

Maintenance with chidamide and azacitidine generated high 3-year overall survival and a low relapse incidence in high-risk AML after allogeneic transplant.

In a phase 2 study, adding venetoclax to ibrutinib rendered BTK C481X resistance mutations undetectable in patients with CLL.

Both the reactive and proactive ibrutinib dose-adjustment cohorts of the phase 2 TAILOR study met the primary ORR end point in previously untreated CLL.

Afami-cel received full FDA approval for unresectable or metastatic synovial sarcoma after prior chemotherapy.

PFS was improved only numerically with the use of maintenance dostarlimab vs observation after chemoradiation in high-risk locally advanced cervical cancer.

Eleven Western New York organizations received funding to advance cancer prevention and early detection.

China’s NMPA has satri-cel for pretreated, CLDN18.2-positive, HER2-negative advanced gastric/GEJ adenocarcinoma.

The STELLAR-303 trial met its OS end point with the zanzalintinib regimen in the ITT population but failed to show the same benefit in the NLM subgroup.